CLSN News and Press, Celsion Corporation From 05/18/22

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potenti...

Celsion Corporation (CLSN) Q1 2022 Earnings Conference Call May 16, 2022 11:00 ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Officer and President Jeff Church - Chief Financial Officer Nicholas Borys - Chief Medical Officer Khursheed A...

Celsion press release (NASDAQ:CLSN): Q1 GAAP EPS of -$1.82 misses by $0.82. Revenue of $0.13M (flat Y/Y) beats by $0.02M. The Company had $47.3 million in cash, investments and restricted cash as of March 31, 2021. For further details see: Celsion GAAP EPS of -$1.82 misse...

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-devel...

Celsion (NASDAQ:CLSN) is scheduled to announce Q4 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$1.02 and the consensus Revenue Estimate is $0.11M Looking at last quarter's earnings report. For further details see: Celsion Q4 2022 Earnings Prev...

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N.J., May 10, 2022 (GLOBE NEWSWIR...

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m...

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible Platform Appears to Show Promise LAWRENCEVILLE, N.J., April 21, 2022 (GLOBE NEWSWIRE)...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clini...